Treatment options for heart failure in individuals with overweight or obesity: a review DOI
Athina Nasoufidou, Panagiotis Stachteas,

Paschalis Karakasis

et al.

Future Cardiology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 15

Published: March 18, 2025

Obesity and heart failure are interlaced global epidemics, each contributing to significant morbidity mortality. is not only a risk-factor for failure, but also complicates its management, by distinctive pathophysiological mechanisms cumulative comorbidities, requiring tailored treatment plan. To present current options in individuals with overweight/obesity, emphasizing available pharmacological therapies, non-pharmacological strategies, the management of related comorbidities. We conducted comprehensive literature review regarding results treatments including cornerstone interventions as well emerging therapeutic options. Specific drug classes, angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, sodium-glucose cotransporter-2 have demonstrated consistent efficacy irrespective body mass index, while diuretics remain key fluid management. Glucagon-like peptide-1 agonists shown promising improving relevant outcomes warrant further research. Non-pharmacological approaches, weight-loss strategies lifestyle modifications, improve symptoms, exercise tolerance quality life. Managing overweight/obesity requires multidisciplinary, individualized approach integrating Emerging therapies preventive arise address unique challenges this population provide improved outcomes.

Language: Английский

Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide DOI Creative Commons

Celestine I. Odigwe,

Rajasekhar Mulyala,

H. A. Malik

et al.

American Heart Journal Plus Cardiology Research and Practice, Journal Year: 2025, Volume and Issue: 52, P. 100518 - 100518

Published: March 1, 2025

Semaglutide, a GLP-1 receptor agonist, has emerged as promising agent in cardiovascular disease management, particularly for patients with obesity and diabetes. Recent studies have demonstrated significant benefits of Semaglutide beyond glycemic control, including reduced major adverse events (MACE), improvements heart failure symptoms, weight reduction. Notably, the STEP-HFpEF trial highlighted improved exercise capacity reduction NT-proBNP levels, offering novel therapeutic pathway management. Additionally, shown anti-inflammatory effects, reducing C-reactive protein (CRP) tumor necrosis factor-alpha (TNF-α), thereby mitigating atherosclerotic risks. Moreover, SELECT Semaglutide's non-diabetic, obese patients, suggesting that its effects extend loss. These findings represent potential paradigm shift risk although access affordability remain key challenges.

Language: Английский

Citations

0
Treatment options for heart failure in individuals with overweight or obesity: a review DOI
Athina Nasoufidou, Panagiotis Stachteas,

Paschalis Karakasis

et al.

Future Cardiology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 15

Published: March 18, 2025

Obesity and heart failure are interlaced global epidemics, each contributing to significant morbidity mortality. is not only a risk-factor for failure, but also complicates its management, by distinctive pathophysiological mechanisms cumulative comorbidities, requiring tailored treatment plan. To present current options in individuals with overweight/obesity, emphasizing available pharmacological therapies, non-pharmacological strategies, the management of related comorbidities. We conducted comprehensive literature review regarding results treatments including cornerstone interventions as well emerging therapeutic options. Specific drug classes, angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, sodium-glucose cotransporter-2 have demonstrated consistent efficacy irrespective body mass index, while diuretics remain key fluid management. Glucagon-like peptide-1 agonists shown promising improving relevant outcomes warrant further research. Non-pharmacological approaches, weight-loss strategies lifestyle modifications, improve symptoms, exercise tolerance quality life. Managing overweight/obesity requires multidisciplinary, individualized approach integrating Emerging therapies preventive arise address unique challenges this population provide improved outcomes.

Language: Английский

Citations

0